{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T21:08:52Z","timestamp":1767474532572},"reference-count":34,"publisher":"The Fukushima Society of Medical Science","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FJMS","Fukushima J. Med. Sci."],"published-print":{"date-parts":[[2016]]},"DOI":"10.5387\/fms.2015-24","type":"journal-article","created":{"date-parts":[[2016,3,14]],"date-time":"2016-03-14T22:07:05Z","timestamp":1457993225000},"page":"36-42","source":"Crossref","is-referenced-by-count":3,"title":["Protection from lethal herpes simplex virus type 1 infection by vaccination with a UL41-deficient recombinant strain"],"prefix":"10.5387","volume":"62","author":[{"given":"Tetsuo","family":"Koshizuka","sequence":"first","affiliation":[{"name":"Department of Microbiology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ishioka","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazufumi","family":"Ikuta","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Suzutani","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3342","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Stanberry LR, Cunningham AL, Mindel A, <i>et al<\/i>.\u3000Prospects for control of herpes simplex virus disease through immunization.\u3000Clin Infect Dis, <b>30<\/b>: 549-566, 2000.","DOI":"10.1086\/313687"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Mindel A, Faherty A, Carney O, Patou G, Freris M, Williams P.\u3000Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes.\u3000Lancet, <b>1<\/b>: 926-928, 1988.","DOI":"10.1016\/S0140-6736(88)91725-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Wald A, Zeh J, Barnum G, Davis LG, Corey L.\u3000Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir.\u3000Ann Intern Med, <b>124<\/b>: 8-15, 1996.","DOI":"10.7326\/0003-4819-124-1_Part_1-199601010-00002"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Fleming DT, McQuillan GM, Johnson RE, <i>et al<\/i>.\u3000Herpes simplex virus type 2 in the United States, 1976 to 1994.\u3000N Engl J Med, <b>337<\/b>: 1105-1111, 1997.","DOI":"10.1056\/NEJM199710163371601"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Straus SE, Corey L, Burke RL, <i>et al<\/i>.\u3000Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes.\u3000Lancet, <b>343<\/b>: 1460-1463, 1994.","DOI":"10.1016\/S0140-6736(94)92581-X"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Straus SE, Wald A, Kost RG, <i>et al<\/i>.\u3000Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial.\u3000J Infect Dis, <b>176<\/b>: 1129-1134, 1997.","DOI":"10.1086\/514103"},{"key":"7","unstructured":"7. Knipe DM, Howley PM.\u3000Fields virology, 6th ed.\u3000Wolters Kluwer\/Lippincott Williams &amp; Wilkins Health, Philadelphia, PA., 2013."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fruh K, Ahn K, Djaballah H, <i>et al<\/i>.\u3000A viral inhibitor of peptide transporters for antigen presentation.\u3000Nature, <b>375<\/b>: 415-418, 1995.","DOI":"10.1038\/375415a0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. York IA, Roop C, Andrews DW, <i>et al<\/i>.\u3000A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes.\u3000Cell, <b>77<\/b>: 525-535, 1994.","DOI":"10.1016\/0092-8674(94)90215-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Imai T, Koyanagi N, Ogawa R, <i>et al<\/i>.\u3000Us3 kinase encoded by herpes simplex virus 1 mediates downregulation of cell surface major histocompatibility complex class I and evasion of CD8+ T cells.\u3000PLoS One <b>8<\/b>: e72050, 2013.","DOI":"10.1371\/journal.pone.0072050"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Frank I, Friedman HM.\u3000A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G.\u3000J Virol, <b>63<\/b>: 4479-4488, 1989.","DOI":"10.1128\/jvi.63.11.4479-4488.1989"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Friedman HM, Cohen GH, Eisenberg RJ, Seidel CA, Cines DB.\u3000Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells.\u3000Nature, <b>309<\/b>: 633-635, 1984.","DOI":"10.1038\/309633a0"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Para MF, Baucke RB, Spear PG.\u3000Glycoprotein gE of herpes simplex virus type 1: effects of anti-gE on virion infectivity and on virus-induced fc-binding receptors.\u3000J Virol, <b>41<\/b>: 129-136, 1982.","DOI":"10.1128\/jvi.41.1.129-136.1982"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hill AB, Barnett BC, McMichael AJ, McGeoch DJ.\u3000HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus types 1 and 2.\u3000J Immunol, <b>152<\/b>: 2736-2741, 1994.","DOI":"10.4049\/jimmunol.152.6.2736"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Suzutani T, Nagamine M, Shibaki T, <i>et al<\/i>.\u3000The role of the UL41 gene of herpes simplex virus type 1 in evasion of non-specific host defence mechanisms during primary infection.\u3000J Gen Virol, <b>81<\/b>: 1763-1771, 2000.","DOI":"10.1099\/0022-1317-81-7-1763"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Becker Y, Tavor E, Asher Y, Berkowitz C, Moyal M.\u3000Effect of herpes simplex virus type-1 UL41 gene on the stability of mRNA from the cellular genes: beta-actin, fibronectin, glucose transporter-1, and docking protein, and on virus intraperitoneal pathogenicity to newborn mice.\u3000Virus Genes, <b>7<\/b>: 133-143, 1993.","DOI":"10.1007\/BF01702393"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Strelow LI, Leib DA.\u3000Role of the virion host shutoff (vhs) of herpes simplex virus type 1 in latency and pathogenesis.\u3000J Virol, <b>69<\/b>: 6779-6786, 1995.","DOI":"10.1128\/jvi.69.11.6779-6786.1995"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yokota S, Yokosawa N, Okabayashi T, <i>et al<\/i>.\u3000Induction of suppressor of cytokine signaling-3 by herpes simplex virus type 1 contributes to inhibition of the interferon signaling pathway.\u3000J Virol, <b>78<\/b>: 6282-6286, 2004.","DOI":"10.1128\/JVI.78.12.6282-6286.2004"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Walker J, Leib DA.\u3000Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shutoff (vhs) function.\u3000Vaccine, <b>16<\/b>: 1-5, 1998.","DOI":"10.1016\/S0264-410X(97)00164-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Walker J, Laycock KA, Pepose JS, Leib DA.\u3000Postexposure vaccination with a virion host shutoff defective mutant reduces UV-B radiation-induced ocular herpes simplex virus shedding in mice.\u3000Vaccine, <b>16<\/b>: 6-8, 1998.","DOI":"10.1016\/S0264-410X(97)00177-1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Suzutani T, Koyano S, Takada M, Yoshida I, Azuma M.\u3000Analysis of the relationship between cellular thymidine kinase activity and virulence of thymidine kinase-negative herpes simplex virus types 1 and 2.\u3000Microbiol Immunol, <b>39<\/b>: 787-794, 1995.","DOI":"10.1111\/j.1348-0421.1995.tb03271.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Suzutani T, Machida H, Sakuma T.\u3000Efficacies of antiherpesvirus nucleosides against two strains of herpes simplex virus type 1 in Vero and human embryo lung fibroblast cells.\u3000Antimicrob Agents Chemother, <b>32<\/b>: 1046-1052, 1988.","DOI":"10.1128\/AAC.32.7.1046"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Bernstein DI, Stanberry LR.\u3000Herpes simplex virus vaccines.\u3000Vaccine, <b>17<\/b>: 1681-1689, 1999.","DOI":"10.1016\/S0264-410X(98)00434-4"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Itoh N, Matsumura N, Ogi A, <i>et al<\/i>.\u3000High prevalence of herpes simplex virus type 2 in acute retinal necrosis syndrome associated with herpes simplex virus in Japan.\u3000Am J Ophthalmol, <b>129<\/b>: 404-405, 2000.","DOI":"10.1016\/S0002-9394(99)00391-8"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Hashido M, Lee FK, Nahmias AJ, Kawana T.\u3000Prevalence of herpes simplex virus type 1- and 2- specific antibodies among the acute, recurrent, and provoked types of female genital herpes.\u3000Microbiol Immunol, <b>41<\/b>: 823-827, 1997.","DOI":"10.1111\/j.1348-0421.1997.tb01935.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Hashido M, Lee FK, Nahmias AJ, <i>et al<\/i>.\u3000An epidemiologic study of herpes simplex virus type 1 and 2 infection in Japan based on type-specific serological assays.\u3000Epidemiol Infect, <b>120<\/b>: 179-186, 1998.","DOI":"10.1017\/S095026889700856X"},{"key":"27","unstructured":"27. Nahmias AJ, Lee FK, Beckman-Nahmias S.\u3000Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world.\u3000Scand J Infect Dis Suppl, <b>69<\/b>: 19-36, 1990."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Sonar S, Lal G.\u3000Role of Tumor Necrosis Factor Superfamily in Neuroinflammation and Autoimmunity.\u3000Front Immunol, <b>6<\/b>: 364, 2015.","DOI":"10.3389\/fimmu.2015.00364"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Sergerie Y, Rivest S, Boivin G.\u3000Tumor necrosis factor-alpha and interleukin-1 beta play a critical role in the resistance against lethal herpes simplex virus encephalitis.\u3000J Infect Dis, <b>196<\/b>: 853-860, 2007.","DOI":"10.1086\/520094"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Belshe RB, Leone PA, Bernstein DI, <i>et al<\/i>.\u3000Herpevac Trial for W.\u3000Efficacy results of a trial of a herpes simplex vaccine.\u3000N Engl J Med, <b>366<\/b>: 34-43, 2012.","DOI":"10.1056\/NEJMoa1103151"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Krause PR, Straus SE.\u3000Herpesvirus vaccines.\u3000Development, controversies, and applications.\u3000Infect Dis Clin North Am, <b>13<\/b>: 61-81, vi., 1999.","DOI":"10.1016\/S0891-5520(05)70043-X"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Langenberg AG, Burke RL, Adair SF, <i>et al<\/i>.\u3000A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected].\u3000Ann Intern Med, <b>122<\/b>: 889-898, 1995.","DOI":"10.7326\/0003-4819-122-12-199506150-00001"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Coleman JL, Shukla D.\u3000Recent advances in vaccine development for herpes simplex virus types I and II.\u3000Hum Vaccin Immunother, <b>9<\/b>: 729-735, 2013.","DOI":"10.4161\/hv.23289"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Yang I, Han SJ, Kaur G, Crane C, Parsa AT.\u3000The role of microglia in central nervous system immunity and glioma immunology.\u3000J Clin Neurosci, 17: 6-10, 2010.","DOI":"10.1016\/j.jocn.2009.05.006"}],"container-title":["FUKUSHIMA JOURNAL OF MEDICAL SCIENCE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/62\/1\/62_2015-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T06:41:05Z","timestamp":1692254465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/62\/1\/62_2015-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.5387\/fms.2015-24","relation":{},"ISSN":["0016-2590","2185-4610"],"issn-type":[{"value":"0016-2590","type":"print"},{"value":"2185-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}